One study by Moiseyenko et al. reported the clinical efficacy of MMC in 12 ovarian cancer patients with germline BRCA1 mutations, suggesting that MMC may target defects in the DNA repair pathway, demonstrating increased activity in patients harboring HRD tumors [31]. Here, BRCA1 is linked to ovarian carcinoma.